Pathological Cardiac Hypertrophy Alters Intracellular Targeting of PDE5 from Nitric Oxide Synthase-3 to Natriuretic Peptide Signaling

[1]  M. Marletta,et al.  Structure and regulation of soluble guanylate cyclase. , 2012, Annual review of biochemistry.

[2]  B. Casadei,et al.  Sub-cellular targeting of constitutive NOS in health and disease. , 2012, Journal of molecular and cellular cardiology.

[3]  R. Fischmeister,et al.  PDEs create local domains of cAMP signaling. , 2012, Journal of molecular and cellular cardiology.

[4]  D. Kass,et al.  Pressure-Overload–Induced Subcellular Relocalization/Oxidation of Soluble Guanylyl Cyclase in the Heart Modulates Enzyme Stimulation , 2012, Circulation research.

[5]  B. French,et al.  Differential Expression of PDE5 in Failing and Nonfailing Human Myocardium , 2012, Circulation. Heart failure.

[6]  L. R. Potter,et al.  Guanylyl cyclase structure, function and regulation. , 2011, Cellular signalling.

[7]  M. Zaccolo,et al.  cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes , 2011 .

[8]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[9]  Dong I. Lee,et al.  Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. , 2010, Journal of the American College of Cardiology.

[10]  R. Fischmeister,et al.  Feedback Control Through cGMP-Dependent Protein Kinase Contributes to Differential Regulation and Compartmentation of cGMP in Rat Cardiac Myocytes , 2010, Circulation research.

[11]  K. Nakao,et al.  Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-A Signaling in the Heart , 2010, Circulation research.

[12]  Xinli Hu,et al.  Oxidative Stress Regulates Left Ventricular PDE5 Expression in the Failing Heart , 2010, Circulation.

[13]  Martin J. Lohse,et al.  β2-Adrenergic Receptor Redistribution in Heart Failure Changes cAMP Compartmentation , 2010, Science.

[14]  M. Houslay.  Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.

[15]  Dong I. Lee,et al.  PDE5A suppression of acute β-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation , 2010, Basic Research in Cardiology.

[16]  H. Otani.  The role of nitric oxide in myocardial repair and remodeling. , 2009, Antioxidants and Redox Signaling.

[17]  K. Sipido,et al.  Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice , 2009, Circulation.

[18]  D. Kass,et al.  Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. , 2009, Journal of the American College of Cardiology.

[19]  Hisham S. Elbatarny,et al.  Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions , 2008, Proceedings of the National Academy of Sciences.

[20]  D. Kass,et al.  Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil , 2008, Journal of Pharmacology and Experimental Therapeutics.

[21]  F. Laurindo,et al.  Assessment of superoxide production and NADPH oxidase activity by HPLC analysis of dihydroethidium oxidation products. , 2008, Methods in enzymology.

[22]  R. Arena,et al.  Long-term use of sildenafil in the therapeutic management of heart failure. , 2007, Journal of the American College of Cardiology.

[23]  P. Light,et al.  Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility , 2007, Circulation.

[24]  Xin Xu,et al.  Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations. , 2007, American journal of physiology. Renal physiology.

[25]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[26]  D. Kass,et al.  Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. , 2007, Journal of the American College of Cardiology.

[27]  G. Lewis,et al.  Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.

[28]  M. Lohse,et al.  Cyclic AMP Imaging in Adult Cardiac Myocytes Reveals Far-Reaching &bgr;1-Adrenergic but Locally Confined &bgr;2-Adrenergic Receptor–Mediated Signaling , 2006, Circulation research.

[29]  L. Langeberg,et al.  AKAP signaling complexes: getting to the heart of the matter. , 2006, Trends in molecular medicine.

[30]  D. Cooper,et al.  Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes , 2006, Circulation.

[31]  ThomasMünzel,et al.  Endothelial Nitric Oxide Synthase in Vascular Disease , 2006 .

[32]  S. Reiken,et al.  Phosphodiesterase 4D Deficiency in the Ryanodine-Receptor Complex Promotes Heart Failure and Arrhythmias , 2005, Cell.

[33]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[34]  Anindita Das,et al.  Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis , 2005, Journal of Biological Chemistry.

[35]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[36]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[37]  M. Guazzi,et al.  The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. , 2004, Journal of the American College of Cardiology.

[38]  R. Karas,et al.  Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure , 2003, Nature Medicine.

[39]  G. Baillie,et al.  Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. , 2003, Cellular signalling.

[40]  Michael D. Schneider,et al.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.

[41]  R. Lefkowitz,et al.  beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  P. Huang,et al.  Modulation of mouse cardiac function in vivo by eNOS and ANP. , 2000, American journal of physiology. Heart and circulatory physiology.

[44]  K. Margulies,et al.  Inhibition of cyclic GMP phosphodiesterases augments renal responses to atrial natriuretic factor in congestive heart failure. , 1994, Journal of cardiac failure.

[45]  M. Wilkins,et al.  Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat. , 1993, The Journal of clinical investigation.